Brought to you by 
Sutro Biopharma's IPO nets $79mm
28 Sep 2018
Executive Summary
Cancer and autoimmune disease drug developer Sutro Biopharma Inc. netted $79mm through its initial public offering of 5.67mm common shares at $15. The company originally intended to sell 5mm shares at a range of $14-16.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sutro Biopharma's IPO nets $79mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice